Spero Therapeutics (SPRO) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Talphera (TLPH) has outperformed Spero Therapeutics (SPRO) over the past year, losing 41.4% versus a loss of 67.9%. Over five years, TLPH leads with a -94.0% price change compared with -95.1% for SPRO. Spero Therapeutics is the larger company by market cap ($43.2 million vs $40.8 million), about 1.1 times the size.
Spero Therapeutics converts more of its revenue into profit, with a net margin of 12.8% versus -51035.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRO | TLPH |
|---|---|---|
| Share price | $0.742 | $0.7852 |
| Market cap | $43.23M | $40.80M |
| 1-day change | -10.20% | +6.25% |
| YTD return | -68.15% | -31.12% |
| 1-year return | -67.88% | -41.40% |
| 5-year return | -95.09% | -93.96% |
| EPS (TTM) | $-0.50 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $66.80M | $28.00K |
| Revenue growth (YoY) | +39.24% | — |
| Net income (latest FY) | $8.57M | $-14.29M |
| Operating margin | 9.45% | -48157.14% |
| Net margin | 12.83% | -51035.71% |
| 52-week high | $3.08 | $1.57 |
| 52-week low | $0.73 | $0.69 |
| Distance from 52-week high | -75.91% | -49.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +573.85% | +298.62% |
| Average volume | 530.46K | 144.13K |
| Shares outstanding | 58.26M | 51.96M |
| Employees | 25 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed SPRO by 26.5 percentage points over the past year.
- Spero Therapeutics is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -51035.7 cents for Talphera.
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
SPRO vs TLPH FAQ
Which is bigger, Spero Therapeutics or Talphera?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $40.80M for Talphera (TLPH).
Which stock has performed better over the past year, SPRO or TLPH?
TLPH returned -41.40% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Spero Therapeutics and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.